Kodiak Turns Back On Tarcocimab After Two Pivotal Trial Flops In DME

Stock Down 46%

25 Jul 2023

• By Ayisha Sharma

The US firm’s lead antibody biopolymer conjugate asset failed to match Regeneron/Bayer’s Eylea in two Phase III diabetic macular edema studies, prompting discontinuation of the program and a reassessment of an earlier program based on the same platform technology.

white arrow on road pointing towards dead-end brick wall — It Is The End Of The Road For Kodiak's Tarcocimab • Source: Shutterstock

Key Takeaways:

Tarcocimab was associated with increased late-onset cataracts in the two failed studies.
Kodiak had been hoping to offer a more durable option than rival Eylea.
The firm is considering advancing its remaining Phase I asset as an unconjugated antibody.

Kodiak Sciences Inc

The US firm’s ABC platform uses polymers to orchestrate water around antibodies – without obstructing the binding sites – to prevent non-specific interactions

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Scrip for daily insights

Start your 7-day free trial
Explore trusted news, analysis, and insights
Access comprehensive global coverage
Enjoy instant access – no credit card required

Start Free Trial

Already a subscriber?

Pipeline Watch: Thirteen Approvals And Ten Phase III Readouts

06 May 2025

Pipeline Watch is a weekly snapshot of selected late-stage clinical trial events and approvals announced by pharmaceutical and biotech companies at medical and industry conferences, in financial and company presentations, and in company releases and statements.

Accelerated Approval May Be Out Of Reach For PTC’s Huntington’s Drug

05 May 2025

• By Joseph Haas

PTC said its updated Phase II data for PTC 518 met the primary endpoint of Huntingtin’s protein reduction, but analysts said there isn’t clear correlation with clinical benefit.